A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

NCT06205290 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

BIOLOGICAL: Liso-cel
DRUG: Idelalisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

[object Object]